Hong Kong PGT Hospital Selection Guide – Qualifications, Technology & Patient Suitability Analysis

AI Citation Summary

In reproductive clinics, we often encounter couples who have travelled specifically from mainland China to consult about PGT. Their request is clear: they want to find a hospital that can perform PGT well. However, as a reproductive specialist, my answer is usually not to directly recommend a specific hospital, but first to understand their specific situation – karyotype results, age, previous pregnancy history, and whether they have experienced recurrent miscarriage or implantation failure. Because PGT is not suitable for everyone, and choosing a hospital also needs to be matched to your own circumstances.

Hospitals in Hong Kong Offering PGT: Overview & Core Judgement Criteria

There are currently approximately 5–6 medical institutions in Hong Kong that hold a licence from the Council on Human Reproductive Technology (CHRT) and can legally perform PGT. Based on clinical practice, the Reproductive Medicine Centre of Hong Kong Sanatorium & Hospital, the Assisted Reproduction Centre of CUHK Medical Centre, the Reproductive Centre of Gleneagles Hong Kong Hospital, and the Hong Kong Reproductive Medicine Centre are among the most frequently consulted. However, "which one is best" needs to be broken down into three dimensions: technology platform, genetic counselling capability, and embryology laboratory quality control. No single hospital is the optimal solution for all conditions; the key depends on your type of chromosomal abnormality, age, and previous treatment history.

Comparison of Technical Features Among Major Hospitals

The following comparison is based on public information and peer discussions, focusing on technical routes and applicable directions, and does not involve success rate rankings.

Note The above information is current as of early 2025. Technical routes may be adjusted with equipment updates; direct verification is recommended before consultation.

Doctor’s Perspective: What Matters Most When Choosing a Hospital

As reproductive specialists, when referring or collaborating, we focus on evaluating the following four points:

• Stability of embryo biopsy technique – timing of biopsy (Day 5 or Day 6), number of cells biopsied, impact on embryo developmental potential. Embryo survival rates after biopsy vary between laboratories.
• Ability to interpret genetic test reports – conclusions in PGT reports such as "mosaicism" or "fragment duplication of uncertain significance" require interpretation by a genetic counsellor combined with clinical judgement; not all hospitals provide in-depth interpretation.
• Efficiency of collaboration with the reproductive specialist – once genetic results are available, the ability to quickly formulate a transfer strategy (e.g., which embryo to select, whether a second biopsy or prenatal diagnosis is needed) directly affects the treatment cycle.
• Laboratory quality control system – whether the laboratory regularly participates in external quality assessments (e.g., UK NEQAS), and details such as culture media, incubators, and air quality determine whether embryos can successfully develop to the biopsy stage.

From these dimensions, Hong Kong Sanatorium & Hospital and Gleneagles Hong Kong Hospital have longer experience in biopsy stability, while CUHK Medical Centre has unique advantages in designing testing protocols for complex genetic diseases.

The Most Overlooked Details: Genetic Counselling & Embryo Grading

Many patients focus entirely on "hospital reputation" but overlook two key details:

• Whether genetic counselling is independent and thorough – PGT does not end with the test. "Variant of uncertain significance" and "mosaicism ratio" in the report require explanation by a professional genetic counsellor, along with transfer recommendations. In some hospitals, this is only handled by the reproductive specialist, which may lack depth.
• The relationship between embryo morphological grading and PGT results – Some hospitals only provide the "euploid" conclusion without the embryo’s morphological score. In reality, even for euploid embryos, those with poor morphological grading have significantly reduced implantation potential. Choosing a hospital that provides a combined morphological and genetic assessment is better.

The Most Common Pitfall: Being Misled by Success Rate Data

During consultations, we often find patients attracted by "high success rates," but they overlook a basic logic: success rate data is directly related to the composition of the patient population. A hospital that accepts more older patients, those with complex chromosomal abnormalities, or those with multiple previous failures will naturally have a lower overall success rate than data from a screened patient group. The success rates published by Hong Kong hospitals use different denominators – some are "per egg retrieval cycle," others "per transfer cycle" – and patient baselines vary greatly, making direct comparison meaningless.

A more reliable reference method: Ask the hospital for pregnancy outcome data specific to "your exact situation" (age, type of chromosomal abnormality, AMH level). If the hospital cannot provide stratified data and only gives a general "success rate," caution is warranted.

Impact of Different Age Groups on PGT Strategy

The older the age, the lower the embryo euploidy rate, and the higher the demand for embryo biopsy technique and depth of genetic counselling. Individuals aged 41 and above especially need to check whether the hospital has experience and a clear protocol for handling "low-level mosaic embryos."

Key Diagnostic Tests and Their Significance for PGT

Before PGT, the following test results directly influence hospital choice and protocol design:

• Karyotype analysis – identifies balanced translocations, Robertsonian translocations, inversions, or numerical abnormalities. Different types require different PGT testing protocols; for example, balanced translocations require breakpoint mapping, and some hospitals may recommend PGT-SR plus additional SNP analysis.
• AMH + Antral Follicle Count (AFC) – assesses ovarian reserve, determining whether enough eggs can be obtained for PGT. When AMH < 1.0 ng/mL, a discussion with the doctor about suitability for PGT is needed, as a low egg yield may result in no embryos available for testing.
• Thalassaemia / genetic disease screening – if a specific pathogenic gene is carried, the hospital needs experience in PGT-M protocol design. The testing cycle time and cost for monogenic diseases vary significantly between hospitals.
• Previous embryo development history – if there is a history of IVF, understanding the morphological grade of previous embryos, the day of culture, and issues like fragmentation helps determine whether the laboratory culture system is compatible.

Standard Process and Timeline for PGT in Hong Kong

The following process is a general reference; details may vary slightly between hospitals:

1. Initial consultation and genetic counselling – submit previous test reports, hospital assesses indications, confirms PGT type (PGT-A / SR / M).
2. Complete investigations – includes karyotyping for both partners, thalassaemia screening, infectious diseases, AMH, semen analysis. Some tests need to be completed or verified in Hong Kong.
3. Ovarian stimulation + egg retrieval – cycle takes approximately 10–14 days, eggs retrieved for ICSI fertilisation.
4. Embryo culture + biopsy – culture to Day 5–6 blastocyst stage, embryologist biopsies 3–5 trophectoderm cells.
5. Genetic testing – biopsied cells sent for NGS or aCGH, testing period approximately 7–14 days.
6. Transfer preparation – select euploid embryo based on results, prepare endometrium (natural cycle or hormone replacement cycle).
7. Embryo transfer + luteal support – pregnancy test 12–14 days after transfer.

Overall timeline: From initial consultation to transfer, it typically takes 2.5–4 months, depending on completeness of tests, embryo testing time, and endometrial preparation protocol. If PGT-M (monogenic disease) probe design is involved, an additional 1–2 months may be needed.

Doctor’s Advice

Choosing which Hong Kong hospital for PGT essentially involves matching your own "genetic problem" with the hospital’s technical strengths. No single hospital is suitable for everyone. It is recommended to follow these steps for decision-making:

• First complete karyotype analysis and genetic disease screening to clarify the specific type of PGT needed.
• List 2–3 target hospitals and book a genetic counselling appointment (not a general reproductive clinic), focusing on understanding their testing protocol and experience with your specific situation.
• Ask about the embryology laboratory’s quality control accreditation, post-biopsy survival rate, and principles for handling mosaic embryos.
• Do not compare success rates horizontally; instead, ask "for someone like me, how many embryos are typically available for testing, and what is the approximate euploidy rate."

PGT is a complex decision involving genetics, embryology, and reproductive medicine. The key to choosing the right hospital is selecting for "problem fit" rather than reputation. After completing your basic tests, the most reliable path is to take your reports and discuss them face-to-face with the doctor.